Corrigendum: Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo (Cell Death and Disease (2014) 5 (e1505) DOI: 10.1038/cddis.2014.465);Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Rocha, C R R ^a   Garcia, C C M ^a   Vieira, D B ^a   Quinet, A ^a   De Andrade Lima, L C ^a   Munford, V ^a   Belizario J E ^a   Menck, C F M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BUTHIONINE SULFOXIMINE; CASPASE 3; CASPASE 7; CISPLATIN; GLUTATHIONE; PROTEIN P53; TEMOZOLOMIDE; DACARBAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CANCER SURVIVAL; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DEPLETION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FEMALE; GLIOMA CELL; HOST CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; BRAIN TUMOR; DEFICIENCY; DISEASE COURSE; DNA DAMAGE; DRUG EFFECTS; DRUG RESISTANCE; GLIOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; BUTHIONINE SULFOXIMINE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DACARBAZINE; DISEASE PROGRESSION; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOMA; GLUTATHIONE; HUMANS; MICE, NUDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84928037804     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.101     Document Type: Erratum

References (38)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
2. Beier D, Schulz J, Beier C. Chemoresistance of glioblastoma cancer stem cells -much more complex than expected. Mol Cancer 2011; 10: 128.
3. Johannessen T-CA, Bjerkvig R. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. Expert Rev Anticancer Ther 2012; 12: 635-642.
4. Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, Menck CFM et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007; 26: 186-197.
5. Batista LFZ, Roos WP, Christmann M, Menck CFM, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007; 67: 11886-11895.
6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-584.
7. Van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer 2006; 42: 582-588.
8. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-1883.
9. Byun S-S, Kim SW, Choi H, Lee C, Lee E. Augmentation of cisplatin sensitivity in cisplatin resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int 2005; 95: 1086-1090.
10. Hoebers FJP, Pluim D, Verheij M, Balm AJM, Bartelink H, Schellens JHM et al. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Int J Cancer 2006; 119: 750-756.
11. Ali-Osman F, Brunner JM, Kutluk TM, Hess K. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 1997; 3: 2253-2261.
12. Olive PL, Banáth JP. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytom Part B 2009; 76B: 79-90.
13. Cleaver JE. γH2Ax: biomarker of damage or functional participant in dna repair 'All that Glitters Is not Gold!'. Photochem Photobiol 2011; 87: 1230-1239.
14. Santos J, Meyer J, Mandavilli B, Houten B. Quantitative PCR-based measurement of nuclear and mitochondrial DNA damage and repair in mammalian cells. DNA Repair 2006: 183-199.
15. Oliva CR, Moellering DR, Gillespie GY, Griguer CE. Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS One 2011; 6: e24665.
16. Kim CK, Nguyen TLX, Joo KM, Nam D-H, Park J, Lee K-H et al. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res 2010; 70: 9730-9741.
17. Datta K, Shah P, Srivastava T, Mathur SG, Chattopadhyay P, Sinha S. Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides. Cancer Gene Ther 2004; 11: 525-531.
18. Tallen U, Truss M, Kunitz F, Wellmann S, Unryn B, Sinn B et al. Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. J Neurooncol 2008; 86: 23-30.
19. Park CM, Park MJ, Kwak HJ, Moon SI, Yoo DH, Lee HC et al. Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Int J Oncol 2006; 28: 119-125.
20. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008; 14: 1291-1295.
21. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772-777.
22. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatinresistant ovarian cancer cells: role of ercc1-xpf. Biochem Pharmacol 2000; 60: 1305-1313.
23. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63: 1311-1316.
24. Chen HHW, Kuo MT. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010; 2010: 430939.
25. Van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; 89: 160-166.
26. Rudin CM, Yang Z, Schumaker LM, Vander Weele DJ, Newkirk K, Egorin MJ et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 2003; 63: 312-318.
27. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14: 249-256.
28. Calvert P, Yao K-S, Hamilton TC, O'Dwyer PJ. Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact 1998; 111: 213-224.
29. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
30. Pegg AE. Repair of O6-alkylguanine by alkyltransferases. Mutat Res 2000; 462: 83-100.
31. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
32. D'Atri S, Graziani G, Lacal PM, Nisticò V, Gilberti S, Faraoni I et al. Attenuation of O6-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 2000; 294: 664-671.
33. Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 2004; 22: 1598-1604.
34. Zustovich F, Lombardi G, Della Puppa A, Rotilio A, Scienza R, Pastorelli D. A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. Anticancer Res 2009; 29: 4275-4279.
35. Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G et al. Phase II trial of cisplatin plus temozol omide, in recurrent and progressive malignant glioma patients. J Neurooncol 2004; 66: 203-208.
36. Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H et al. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Cancer Lett 2013; 331: 68-75.
37. Tentori L, Dorio AS, Mazzon E, Muzi A, Sau A, Cuzzocrea S et al. The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma. Eur J Cancer 2011; 47: 1219-1230.
38. Soltys DT, Rocha CRR, Lerner LK, de Souza TA, Munford VCabral F et al. Novel XPG (ERCC5) mutations affect DNA repair and cell survival after ultraviolet but not oxidative stress. Hum Mutat 2013; 34: 481-489.